Periodic Reporting for period 1 - Syndivia (Next generation drug conjugates for cancer treatment)
Reporting period: 2016-07-01 to 2016-11-30
Pancreatic cancer has the lowest survival rate of all cancers and is the fourth leading cause of death by cancer in Europe. Syndivia has developed SDV1001, a small molecule prodrug customised to target the pancreatic tumour microenvironment upon conjugation with serum albumin found in blood. The formulation offers a specialist target therapy for treating cancer without harming healthy cells surrounding the tumour. The objectives of the innovation project are to advance the drug through preclinical toxicology studies and commence Phase I/IIa clinical trials with cancer patients.
Syndivia undertook a full analysis of the both the technical and business potential of the SDV1001 prodrug. Syndivia analysed results of early preclinical trials and the efficacy of the product was proven through the treatment of mice. The response to SDV1001 displayed 92-100% tumour regression and no noticeable side effects. Syndivia also evaluated the strategy for out-licensing later development and performed detailed projections for the company growth. Syndivia also outreached many potential customers and stakeholders building a strong base in the oncology and pharma networks.
The expected outcome of the project is to gain first results from clinical trials and advance toward the out-licensing of the prodrug. If clinical trials are successful, the SDV1001 will be a highly valuable investment for pharmaceutical companies. The SDV1001 development will boost economic growth and create jobs within Syndivia and on a wider scale with CMOs and CROs in Europe.